Akari Therapeutics (AKTX) Short-Term Debt repayments (2024 - 2026)

Akari Therapeutics has disclosed Short-Term Debt repayments across 3 years of filings, most recently posting $102000.0 for Q1 2026.

• Short-Term Debt repayments for Q1 2026 came in at $102000.0, down 5.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $493000.0 (down 50.6% YoY), and the FY2025 annual result was $499000.0, down 54.84% from the prior year.
• Short-Term Debt repayments came in at $102000.0 for Q1 2026 at Akari Therapeutics, up from $57000.0 in the prior quarter.
• In the past five years, Short-Term Debt repayments ranged from a high of $336000.0 in Q3 2024 to a low of $57000.0 in Q4 2025.
• The 3-year median for Short-Term Debt repayments is $169000.0 (2025), against an average of $189555.6.
• Across the five-year window, Short-Term Debt repayments slumped 74.44% in 2025 and decreased 5.56% in 2026, its largest moves.
• Akari Therapeutics' Short-Term Debt repayments stood at $223000.0 in 2024, then sank by 74.44% to $57000.0 in 2025, then soared by 78.95% to $102000.0 in 2026.
• The last three Short-Term Debt repayments figures came in at $102000.0 (Q1 2026), $57000.0 (Q4 2025), and $169000.0 (Q3 2025), per Business Quant data.